Tiny study tests smart sugar tracking for breast cancer drug side effect

NCT ID NCT06083038

Completed Symptom relief Sponsor: HealthPartners Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 8 adults with metastatic breast cancer who were starting the drug alpelisib. Alpelisib often causes high blood sugar, so researchers used a continuous glucose monitor (a small sensor worn on the arm) to track glucose levels day and night for at least 3 months. The goal was to understand when blood sugar spikes happen and to help manage them with a prevention plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alpelisib
What this could lead to: If successful, this could lead to better ways to manage high blood sugar caused by alpelisib, making treatment more tolerable for breast cancer patients.
What could go wrong: This is a very small, completed observational study with only 8 participants, so results may not apply to everyone. It does not test a new treatment for cancer itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

HealthPartners Cancer Research Center

Saint Louis Park, Minnesota, 55426, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.